Figure 2.

Epithelial cancers, and SCCs in particular, share numerous common biological underpinnings, including dysregulation of the METTL3-m⁶A epitranscriptome. To date, studies have demonstrated consistent overexpression of METTL3 across these cancers. As detailed further in the text and Table 1, depending upon the cancer, other writers (purple), readers (pink), erasers (green), and adaptors (gray) have been shown to display dysregulated expression or activity, ultimately driving m⁶A disruption and carcinogenesis through diverse mechanisms, such as oncogene activation or therapy resistance. Cancers listed include bladder cancer (BLCA), cutaneous SCC (cSCC), head and neck SCC (HNSCC), esophageal SCC (ESCC), cervical SCC (CESC), and lung SCC (LUSC).